Improving Outcomes in Patients With SSc-ILD

Slides:

Advertisements

Similar presentations

Early detection of pulmonary involvement in scleroderma patients By Mohamed Mostafa Metwally, MD, FCCP Assistant professor of chest diseases Assiut University.

Advertisements

Chen R et al. Proc ASH 2015;Abstract 518.

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Exploring Early Combination Therapy in PAH

Primary Care Challenges in Depression - To Treat or Refer?

Chronic Hepatitis C Virus Infection

Demystifying Idiopathic Pulmonary Fibrosis

Starting Strong: Initial Evaluation of the Patient With HCV

NOACs In Long-term VTE Treatment: A State Of The Art Review

Optimizing Therapy for Osteoarthritis

Advanced NSCLC Without Actionable Mutations

An Update on Oral Prostanoids: Advancing Care for PAH?

Optimizing Use of Biological Agents in Ulcerative Colitis

Changing the IBD Paradigm

UNDERSTANDING RISK STRATIFICATION IN PAH:

Modifying Disease Course in Alzheimer's Disease

What Predicts Disability Progression in Multiple Sclerosis?

Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.

Select Topics in Cardiovascular Medicine

Optimizing Outcomes in the Management of GIST

The Cancer Pain Journey: Optimizing Identification and Management

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

Goals of Therapy in Relapsed CLL

A Closer Look at Pemphigus Vulgaris: Clinical Challenges and Emerging Treatments.

Optimizing Patient Outcomes in IBD

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

Decision-making in the eRA of Treating to Target

Disease Activity Assessment Across the RA Continuum

PAH Therapy Revisited.

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Precision Management of RA and Comorbidities

Activity Goals. Activity Goals Case Presentation.

Case Collection in RA: Highlights of an Interactive Workshop

Multidisciplinary Perspectives on Interstitial Lung Diseases

Is RA Treatment Addressing the Real Needs of Patients?

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.

Treating to Target in MS

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Systemic Sclerosis With Interstitial Lung Disease

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Future Directions in Myelofibrosis: Implications of Emerging Approaches.

Approaches in Newly Diagnosed Multiple Myeloma: When and What

The Evolving Treatment Landscape in Atopic Dermatitis

Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.

Maintenance Therapy in Advanced Ovarian Cancer

Cancer-Associated Thrombosis

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

New ELN Recommendations

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

Practical Guidance on the Management of Pan-Negative NSCLC

Proteasome Inhibitors and Patients

Communicating With Your Patients About Major Depressive Disorder

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Reducing Risk for CV Outcomes

The Patient With Early Stage MF-CTCL

Program Goals Overview Is NEDA a Reasonable Target?

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Figure 2 Proposed approach to treating myositis-associated interstitial lung disease Figure 2 | Proposed approach to treating myositis-associated interstitial.

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

PAH Pathways: What Do the Data Tell Us?”

Early Diagnosis and Management of SSc-ILD

Exploring the Use of Adeno-Associated Virus for Gene Therapy

NAFLD and NASH in Europe and Canada

Treatment Advances for RA

Treatment Initiation and Selection in Newly Diagnosed CLL

Management of NTM Lung Disease

Presentation transcript:

Improving Outcomes in Patients With SSc-ILD

Introduction

Overview of Major SSc Complications

Prevalence of ILD in Patients with SSc

ILD Appears Early in the Course of SSc

Importance of Identifying SSc-ILD Patients at Risk of Progression

Identification of Patients at Risk of Disease Progression Is the Key

Disease Progression: Definition

Predicting Factors for Progressive ILD

Screening for ILD Using HRCT and PFTs

How to Screen for ILD

FVC and HRCT to Evaluate Patients with SSc-ILD

Tools for Screening

Who to Screen?

Example of Algorithm Used to Determine When Treatment for SSc-ILD Should Be Initiated: University of California

Example of Algorithm Used to Determine When Treatment for SSc-ILD Should Be Initiated: University of California (cont)

Who to Treat?

Who to Treat (cont)

What Are the Treatment Goals in SSc-ILD?

Oral Cyclophosphamide in SSc-PF: SLS-I

SLS II Primary Outcome Assessment

ASCT for DcSSc

ASCT vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis

What Are the Unmet Needs With Current Therapies?

Intensity to Treat to Get Remission

Rituximab EUSTAR Observational Study

Targeted Therapies in SSc/SSc-ILD

SLS-III Phase 2 Trial With Pirfenidone

Tocilizumab: focuSSced Phase 3 Study

SENSCIS Phase 3 Trial With Nintedanib

Management of SSc-ILD

How to Follow Up

Case Presentation

Evolution

Evolution (cont)

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)